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Abstract 
Background 
Long-term outcomes following ventricular tachycardia (VT) ablation are sparsely 
described. 
 
Objectives 
To describe long term prognosis following VT ablation in patients with no structural 
heart disease (no SHD), ischemic (ICM) and non-ischemic cardiomyopathy (NICM). 
 
Methods 
Consecutive patients (n=695; no SHD 98, ICM 358, NICM 239 patients) ablated for 
sustained VT were followed for a median of 6 years. Acute procedural parameters 
(complete success [non-inducibility of any VT]) and outcomes after multiple procedures 
were reported.  
 
Results 
Compared with patients with no SHD or NICM, ICM patients were the oldest, had more 
males, lowest left ventricular ejection fraction (LVEF), highest drug failures, VT storms 
and number of inducible VTs. Complete procedure success was highest in no SHD, 
compared ICM and NICM patients (79%, 56%, 60% respectively, P<0.001). At 6 years, 
ventricular arrhythmia (VA)-free survival was highest in no SHD (77%) than ICM (54%) 
and NICM (38%, P<0.001) and overall survival was lowest in ICM (48%), followed by 
NICM (74%) and no SHD patients (100%, P<0.001). Age, LVEF, presence of SHD, 
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acute procedural success (non-inducibility of any VT), major complications, need for 
non-radiofrequency ablation modalities, and VA recurrence were independently 
associated with all cause mortality. 
 
Conclusions 
Long term follow up following VT ablation shows excellent prognosis in the absence of 
SHD, highest VA recurrence and transplantation in NICM and highest mortality in 
patients with ICM. The extremely low mortality for those without SHD suggests that VT 
in this population is very rarely an initial presentation of a myopathic process. 
 
Keywords: ventricular tachycardia; catheter ablation; structural heart disease; ischemic 
cardiomyopathy; non-ischemic cardiomyopathy.  
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Introduction 
Catheter ablation for sustained monomorphic ventricular tachycardia (VT), as an 
adjunct to medical therapy reduces the morbidity associated recurrent VT.
1
 Prior studies 
on outcomes following VT ablation report a limited duration of follow up, mostly up to 2 
years; thus data on long-term recurrence and mortality following VT ablation is limited.
2, 
3
 Furthermore, whilst substrate differences between ischemic and non-ischemic 
cardiomyopathy (ICM and NICM respectively) have been appreciated,
4
 few studies have 
directly compared the outcomes of these groups in follow up, or have been underpowered 
to detect differences in major endpoints such as mortality and transplantation or have 
lacked a control group of patients without structural heart disease (SHD).
5, 6
 In this study, 
we followed 695 consecutive patients either with no SHD, ICM or NICM for a median of 
6 years to directly compare the acute procedural efficacy and long-term prognosis in 
these groups following catheter ablation of sustained monomorphic VT. We also 
examined clinical and procedural factors for their ability to predict recurrent ventricular 
arrhythmia (VA), and mortality following VT ablation. 
 
Methods 
This was a retrospective series of 695 consecutive patients who presented for catheter 
ablation of sustained monomorphic VT between 1999-2009 at Brigham and Women’s 
Hospital. The patient population consisted of 98 patients with no SHD diagnosed with 
idiopathic sustained VT, 358 patients with ICM and 239 patients with NICM. 
All patients underwent echocardiography and/or magnetic resonance imaging to 
screen for the presence of SHD and to define ventricular function. The distinction 
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between ICM and NICM was based primarily on the presence of relevant coronary artery 
disease confirmed with a coronary angiography. NICM was identified as an absence of 
relevant coronary artery disease and defined according to the criteria of the European 
Society of Cardiology Working Group for Myocardial and Pericardial Diseases.
7
 Patients 
with premature ventricular contractions or ventricular fibrillation (VF) induced by 
premature ventricular contractions as the procedural indication were excluded. All 
patients gave written informed consent for the procedure and the study analysis was 
performed according to protocols approved by the Brigham and Women’s Hospital 
Human Subject Protection Committee. 
 
Mapping and Ablation 
Our approach to percutaneous endocardial and epicardial mapping and ablation has been 
described previously.
8
 Briefly, programmed ventricular stimulation was performed with 
≤3 extrastimuli after a drive train of 600 milliseconds [ms] and 400 ms from 2 right 
ventricular (RV) sites, and repeated from at least one left ventricular (LV) site if VT was 
non-inducible from RV stimulation. Isoprenaline or epinephrine was used upon the 
discretion of the operator. This protocol was repeated after ablation. 
The morphologies of the induced VTs were compared to the spontaneously 
occurring VT(s) prior to ablation. Sustained monomorphic VT was defined as continuous 
VT for ≥30 seconds or one that required an intervention for termination (cardioversion, 
pacing or ablation).
9
 
We defined “spontaneous VT” as any inducible VT with an identical 12-lead 
EKG morphology and rate (within 20 ms) to a VT that the patient presented with prior to 
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ablation. If 12-lead EKGs of the presenting VT were not available prior to ablation, the 
rate cut off and intracardiac electrogram (EGM) characteristics from the implantable 
cardioverter defibrillator (ICD) were used. “Undocumented VTs” were defined as 
inducible VTs that had a different cycle length (>20 ms difference), 12-lead EKG 
morphology or ICD-derived electrogram (EGM) characteristics compared to the VT that 
the patient had presented with prior to ablation.
9
 
For VT associated with SHD, substrate mapping was performed with particular 
focus on pace-mapping in areas of low voltage (typically <1.5 millivolt [mV] bipolar 
electrograms) scar region facilitated by an irrigated catheter, and the CARTO 
electroanatomic mapping system (Biosense Webster, Diamond Bar, CA, USA). Areas of 
low voltage (<1.5 mV), dense scar (≤0.5mV) and electrically unexcitable scar were 
identified. Late potentials in the scar were tagged. Pace mapping was performed; areas of 
long stimulus to QRS (S-QRS) delays (>40 ms) and where pace mapping matched QRS 
morphology of an induced VT were tagged. If hemodynamically tolerated, VT was re-
induced and activation/entrainment mapping performed. If not tolerated, it was 
terminated with radiofrequency ablation (RFA), burst pacing or cardioversion and 
substrate mapping performed. Ablation targeted presumptive channels, exits within the 
low-voltage area including regions of long S-QRS delays.
10
 RFA was delivered with an 
irrigated catheter (ThermoCool or ThermoCool SF; Biosense Webster) at a power of 25 
to 50 Watts targeting an impedance drop of 10 to 20 ohms. Applications were repeated at 
target areas until they were rendered electrically unexcitable with unipolar pacing at 10 
milliamps at 2-ms pulse width.
10
 Epicardial mapping was performed using the 
percutaneous approach if VT was suspected to be of epicardial origin, or if endocardial 
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ablation failed to terminate VT.
11
 Coronary angiography was performed before epicardial 
ablation to avoid coronary injury; high output pacing was also performed to avoid 
ablation in close proximity to the phrenic nerve.  
Intramural arrhythmia origin was inferred using published criteria as described in 
Supplemental Methods. Adjunctive non-RFA ablative methods such as transcoronary 
ethanol ablation (TCEA) or surgical cryoablation were performed when attempts at 
endocardial and/or epicardial mapping (where relevant), in addition to anti-arrhythmic 
(AAD) drugs failed to control VT. TCEA and surgical cryoablation was performed using 
techniques reported previously.
8
 
 The approach to the ablation of idiopathic VT relied on a combination on 
assessment of putative origin based on 12 lead EKG morphology, activation mapping 
during VT, assessment of pre-potentials and entrainment mapping (if possible) for 
fascicular VT and/or pace mapping when the VT was not reliably sustained or 
hemodynamically tolerated (for papillary muscle, LV summit or RV outflow tract VTs). 
Voltage and entrainment mapping were performed to exclude scar-mediated re-entry. 
 
Outcomes 
Acute procedural outcomes were reported as: 
(a) complete success (defined as non-inducibility of any VT, either “spontaneous” 
and “undocumented”); 
(b) partial success (defined as abolishment of at least one “spontaneous” VT, but 
other “spontaneous” or “undocumented” VTs remained inducible); 
(c) failure (persistent inducibility of “spontaneous” VT). 
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In follow up, outcomes reported were: 
(a) VA-free survival: defined as any VT or VF that required treatment 
with AADs, internal or external cardioversion or anti-tachycardia 
pacing; 
(b)  survival free of cardiac transplantation; 
(c) overall survival; 
Outcomes were reported after the final procedure (multi-procedure outcomes, where 
relevant). The definition of major complications is detailed in Supplemental Methods. 
 
Follow-Up 
Follow up was defined from the time of the final ablation procedure to the time of 
death or last clinical follow up. Follow-up included review of records of all hospital and 
outpatient clinic visits and discussion with referring cardiologists and primary care 
physicians. The National Social Security Death Index was searched for mortality 
information. The approach to AAD management and defibrillator programming is 
detailed in Supplemental Methods. 
 
Statistical Analysis 
The Statistical Package for the Social Sciences for Windows (IBM SPSS, release 23, 
Armonk, NY, USA) was used for analysis. Continuous variables were expressed as mean 
± standard deviation if normally distributed; median and interquartile range 25% to 75% 
(Q25–Q75) or full ranges were used if the data were clearly skewed. Where normal 
distribution was not present, log transformation of the raw values was performed to meet 
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the assumption of homogeneity of variance. Where applicable, paired sample t test was 
performed using the raw values (if normally distributed) or log-transformed values (if not 
normally distributed). Acute procedural success and complications were compared as 
categorical variables using the Fisher’s Exact test. Overall survival, survival free of VA 
and transplant-free survival were estimated using the Kaplan–Meier procedure. Cox-
proportional Hazard models were created to determine predictors of VA recurrence and 
all cause mortality. Models predicting mortality used recurrence as a time-dependent co-
variable. Hazard ratios (HR) and 95% confidence intervals (CI) were used to express risk 
of VA recurrence and mortality. A two-tailed P value <0.05 was considered statistically 
significant. 
 
Results 
Baseline demographics 
Relevant baseline characteristics are shown in Table 1. ICM patients were older, were 
more likely to be male, had greater left ventricular dysfunction, failed more anti-
arrhythmic drugs prior to referral for catheter ablation, and had more refractory VT 
despite amiodarone compared to patients with no SHD and NICM (Table 1).  
 
Procedural characteristics 
More patients with ICM had a history of VT storm or incessant VT, compared with 
patients with NICM or no SHD (Table 2). ICM patients had a greater number of 
inducible VTs and longer ablation times compared to patients with no SHD or NICM. 
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Patients with NICM underwent a greater number of procedures for VT control than 
patients with ICM and those with no SHD. 
Epicardial ablation was more frequently performed in the NICM patients 
compared to patients with no SHD or ICM. Adjunctive non-RFA ablation with TCEA or 
surgical cryoablation for VT refractory to anti-arrhythmic drugs and percutaneous 
ablation was performed with equal frequency in ICM and NICM patients; none of the 
SHD patients required an adjunctive non-RFA ablation (Table 2). Three patients had pre-
existing mechanical LV assist devices but mechanical hemodynamic support was not 
used for ablation in any other patients. 
 
Acute ablation outcomes 
Acute complete success was achieved in 79% of no SHD, 60% of ICM and 56% of 
NICM patients (P<0.001 no SHD vs. others, P=0.4 ICM vs. NICM; Table 2). Partial 
success and/or failure were least common in patients with no SHD patients, but they were 
similar in the patients with ICM vs. NICM (Table 2). 
Major complications were numerically lower in patients with no SHD (3.7%) 
compared with NICM patients (6.7%) and ICM patients (8.3%) but these differences 
were not statistically significant (Table 2, Supplemental Table 1).  
 
Ventricular arrhythmia recurrences in follow up 
Median follow up from the last ablation procedure was 6 years (Q25-Q75: 3-9 years). 
VA-free survival at median follow up in patients with no SHD was greater than ICM and 
NICM patients (77±5%, 54±4% and 38±4%, respectively; Figure 1). Early VA 
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recurrence, within 7 days of the procedure, occurred in 41% of SHD, 39% of NICM and 
32% of ICM patients, respectively  (P=0.5). 
Factors associated with VA recurrence on multivariable analysis were LV ejection 
fraction (LVEF), presence of SHD (compared to no SHD), number of anti-arrhythmic 
drug failures, acute complete success at the end of the procedure, and epicardial ablation 
(Table 3; Supplemental Table 2). After adjusting for these factors, risk of VA recurrence 
was significantly lower in ICM vs. NICM patients (HR 0.7, 95% CI 0.6-0.9, P=0.02). 
 
Mortality and Transplantation 
Survival at median follow up in patients with no SHD was greater than NICM and ICM 
patients (100%, 74±3% and 48±3%, respectively; Figure 2). Survival free of cardiac 
transplant at median follow up in patients with no SHD was greater than ICM and NICM 
patients (100%, 96% and 89±2%, respectively; Figure 3). 
 
Predictors of mortality 
Factors associated with all cause mortality on multivariable analysis were age, LV 
ejection fraction, presence of SHD (versus no SHD), acute complete success, need for 
adjunctive non-RFA ablation methods, occurrence of a major complication and VA 
recurrence during follow up (Table 3; Supplemental Table 3). After adjusting for these 
factors, there was no significant difference in all cause mortality between the NICM vs. 
ICM patients (HR 1.1, 95% CI 0.8-1.5, P=0.5) even when VA recurrence was excluded 
from the model (no change in HR or 95% CI).  
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Factors associated with all cause mortality on multivariable analysis were 
different amongst patients with ICM versus NICM. In ICM patients alone, age, LVEF, 
acute complete success and VA recurrence during follow up were associated with all 
cause mortality on multivariable analysis (Supplemental Table 4). The same factors were 
also associated with all cause mortality in NICM patients, however the occurrence of a 
major complication were also associated whilst acute complete success was no longer 
associated with all cause mortality (Supplemental Table 5).  
 
Discussion 
This study catalogues the acute procedural and long-term outcomes of a large cohort of 
695 patients followed for a median of 6 years and conveys a number of important 
findings: 
1. The excellent prognosis in terms of survival free of death or transplant (100%) 
suggests that VT in patients without SHD is very rarely an initial presentation of a 
myopathic process;  
2. Mortality is highest in ICM patients, such that half have died by 6 years after VT 
ablation; 
3. VA recurrence is highest in NICM patients (three-quarters of patients have 
experienced at least one VA recurrence by 6 years after ablation); rates of cardiac 
transplantation are also highest in this population (11%). Whilst mortality is lower 
than ICM, it remains substantial in that 25% have died by 6 years after ablation; 
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4. Factors such as LVEF, presence of NICM, number of failed AADs, acute non-
inducibility of any VT at the end of the procedure and need for epicardial ablation 
were independently associated with VA recurrence; 
5. Age, LVEF, non-inducibility of any VT at the end of the procedure, need for 
adjunctive non-RFA treatment methods, occurrence of a major procedural 
complication and VA recurrence were independently associated with all cause 
mortality. 
 
Prior studies 
Prior prospective studies (including randomized trials) reporting outcomes of catheter 
ablation of sustained monomorphic VT have had a short duration of follow up, ranging 
from 6-24 months.
5, 12-14
 As such, data on long term outcomes following VT ablation is 
limited, extending to 4 years in a retrospective study in patients with non-ischemic 
cardiomyopathy
15
, 5 years in a retrospective study on arrhythmogenic right ventricular 
dysplasia,
3
 and up to 3 years in a recent post-approval Multicenter Thermocool 
Ventricular Tachycardia Ablation Trial in patients with ICM.
2
 
Whilst fundamental differences in VT substrate in the post-infarction versus non-
ischemic cardiomyopathy has been appreciated,
4, 16
 only a few studies have compared the 
long-term outcomes between these patients and none have been sufficiently powered to, 
nor detected, any differences in endpoints of mortality and transplantation.
5, 6, 16
 Although 
prior studies have examined the predictive value of acute non-inducibility of VT at the 
end of the procedure for future recurrence of VA and mortality,
17-19
 and of VA recurrence 
itself on mortality,
20
 these studies have either been limited to a post-infarction setting,
17, 18
 
 14 
or have analyzed a mixture of patients with both forms of heart disease.
20
 Hence, the 
inter-relationship between clinical and acute procedural outcomes, in addition to VA 
recurrence and its influence on long-term mortality amongst specific disease substrates of 
ICM and NICM remains incompletely studied. 
In this study, we provide detailed information on VA recurrence, transplantation 
and mortality by following one of the largest reported groups of patients with SHD for a 
median of 6 years. The study allows critical appraisal of long-term VT ablation 
outcomes, thus facilitating patient selection and providing information pertaining to the 
prognostic significance of intra-procedural parameters (e.g. need for adjunctive non-RFA 
modalities) and post-procedural endpoints (e.g. non-inducibility of any VT, major 
complications). An advantage of a large single center report is the near uniform VT 
ablation protocol. In contrast, prior multi-center reports encompass heterogeneous 
ablation approaches.
18, 20
 
The overall survival of ICM patients was worse than NICM patients even though 
there were more VA recurrences in the NICM patients. The worse mortality is likely 
related to worse LVEF and older age in ICM compared to NICM patients. The longer 
survival of NICM may also allow more time for recurrent VAs. It is important to 
recognize that these differences may have a major impact on the different outcomes in 
ICM vs. NICM patients that may not be completely accounted for in statistical models. 
Our SHD patients had recurrent arrhythmias and severely depressed ventricular 
function, characteristic of advanced heart disease. The population had a lower mean 
LVEF, a higher proportion of patients with a very low LVEF of ≤30% and more patients 
who had failed amiodarone prior to VT ablation compared to the ablation arms of the 
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SMASH-VT
13
 or the V-TACH studies.
12
 Thus our population represents a higher risk 
cohort with likely more advanced heart disease and later referral for VT ablation. As has 
been suggested by others,
21, 22
 earlier use of catheter ablation may have improved 
outcomes in our cohort and warrants further study. The present study also has a long 
recruitment period during which time procedural techniques evolved with improvements 
in mapping and ablation technologies and strategies that will hopefully translate to better 
outcomes. 
 
Limitations 
This is a retrospective report from a high volume center for VT ablation. It is possible 
other confounding variables not collected may have added to the VA recurrence or 
mortality risk in the study. Furthermore, referral biases are present such that results may 
be skewed to the sickest cohort of ICM and NICM patients that may limit 
generalizability. However this is one of the largest series reporting outcomes with the 
longest duration of follow up of any prior study. 
 
Conclusions 
Long term follow up after VT ablation demonstrates the benign prognosis in patients 
without SHD, suggesting that VT is this population is very rarely an initial presentation 
of a myopathic process. Despite the advanced heart disease typically present in patients 
with VT due to structural heart disease, survival beyond 5 years is common. Patients with 
ICM face the highest mortality risk such that more than half died by 6 years post ablation. 
In contrast, NICM patients face the highest risk of VA recurrence such that three-quarters 
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experienced a recurrence, one tenth were transplanted and one-quarter died by 6 years 
following VT ablation. The higher mortality risk in ICM compared with NICM patients 
was explained by factors such as age, LVEF, acute procedural success and complications, 
challenging substrates requiring adjunctive non-RFA ablation modalities and recurrence 
of VA in follow up.  
 
References 
 
1. Sapp JL, Wells GA, Parkash R, et al. Ventricular Tachycardia Ablation versus 
Escalation of Antiarrhythmic Drugs. N Engl J Med 2016 [Epub ahead of print] 
2. Marchlinski FE, Haffajee CI, Beshai JF, Dickfeld TM, Gonzalez MD, Hsia HH, 
Schuger CD, Beckman KJ, Bogun FM, Pollak SJ, Bhandari AK. Long-Term 
Success of Irrigated Radiofrequency Catheter Ablation of Sustained Ventricular 
Tachycardia: Post-Approval THERMOCOOL VT Trial. J Am Coll Cardiol 
2016;67:674-683. 
3. Santangeli P, Zado ES, Supple GE, Haqqani HM, Garcia FC, Tschabrunn CM, 
Callans DJ, Lin D, Dixit S, Hutchinson MD, Riley MP, Marchlinski FE. Long-
Term Outcome With Catheter Ablation of Ventricular Tachycardia in Patients 
With Arrhythmogenic Right Ventricular Cardiomyopathy. Circ Arrhythm 
Electrophysiol 2015;8:1413-1421. 
4. Soejima K, Stevenson WG, Sapp JL, Selwyn AP, Couper G, Epstein LM. 
Endocardial and epicardial radiofrequency ablation of ventricular tachycardia 
 17 
associated with dilated cardiomyopathy: the importance of low-voltage scars. J 
Am Coll Cardiol 2004;43:1834-1842. 
5. Dinov B, Fiedler L, Schonbauer R, Bollmann A, Rolf S, Piorkowski C, Hindricks 
G, Arya A. Outcomes in catheter ablation of ventricular tachycardia in dilated 
nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results 
from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation 
2014;129:728-736. 
6. Proietti R, Essebag V, Beardsall J, et al. Substrate-guided ablation of 
haemodynamically tolerated and untolerated ventricular tachycardia in patients 
with structural heart disease: effect of cardiomyopathy type and acute success on 
long-term outcome. Europace 2015;17:461-467. 
7. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: 
a position statement from the European Society Of Cardiology Working Group on 
Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-276. 
8. Kumar S, Barbhaiya CR, Sobieszczyk P, et al. Role of Alternative Interventional 
Procedures When Endo- and Epicardial Catheter Ablation Attempts for 
Ventricular Arrhythmias Fail. Circ Arrhythm Electrophysiol 2015;8:606-615. 
9. Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. EHRA/HRS Expert 
Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a 
partnership with the European Heart Rhythm Association (EHRA), a Registered 
Branch of the European Society of Cardiology (ESC), and the Heart Rhythm 
Society (HRS); in collaboration with the American College of Cardiology (ACC) 
and the American Heart Association (AHA). Heart Rhythm 2009;6:886-933. 
 18 
10. Soejima K, Stevenson WG, Maisel WH, Sapp JL, Epstein LM. Electrically 
unexcitable scar mapping based on pacing threshold for identification of the 
reentry circuit isthmus: feasibility for guiding ventricular tachycardia ablation. 
Circulation 2002;106:1678-1683. 
11. Kumar S, Bazaz R, Barbhaiya CR, et al. "Needle-in-needle" epicardial access: 
Preliminary observations with a modified technique for facilitating epicardial 
interventional procedures. Heart Rhythm 2015;12:1691-1697. 
12. Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacretaz E, 
Pitschner HF, Kautzner J, Schumacher B, Hansen PS, group Vs. Catheter ablation 
of stable ventricular tachycardia before defibrillator implantation in patients with 
coronary heart disease (VTACH): a multicentre randomised controlled trial. 
Lancet 2010;375:31-40. 
13. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, 
Jongnarangsin K, Kralovec S, Sediva L, Ruskin JN, Josephson ME. Prophylactic 
catheter ablation for the prevention of defibrillator therapy. N Engl J Med 
2007;357:2657-2665. 
14. Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter 
ablation guided by electroanatomic mapping for recurrent ventricular tachycardia 
after myocardial infarction: the multicenter thermocool ventricular tachycardia 
ablation trial. Circulation 2008;118:2773-2782. 
15. Tokuda M, Tedrow UB, Kojodjojo P, Inada K, Koplan BA, Michaud GF, John 
RM, Epstein LM, Stevenson WG. Catheter ablation of ventricular tachycardia in 
nonischemic heart disease. Circ Arrhythm Electrophysiol 2012;5:992-1000. 
 19 
16. Nakahara S, Tung R, Ramirez RJ, Michowitz Y, Vaseghi M, Buch E, Gima J, 
Wiener I, Mahajan A, Boyle NG, Shivkumar K. Characterization of the 
arrhythmogenic substrate in ischemic and nonischemic cardiomyopathy 
implications for catheter ablation of hemodynamically unstable ventricular 
tachycardia. J Am Coll Cardiol 2010;55:2355-2365. 
17. Ghanbari H, Baser K, Yokokawa M, Stevenson W, Della Bella P, Vergara P, 
Deneke T, Kuck KH, Kottkamp H, Fei S, Morady F, Bogun F. Noninducibility in 
postinfarction ventricular tachycardia as an end point for ventricular tachycardia 
ablation and its effects on outcomes: a meta-analysis. Circ Arrhythm 
Electrophysiol 2014;7:677-683. 
18. Yokokawa M, Kim HM, Baser K, et al. Predictive value of programmed 
ventricular stimulation after catheter ablation of post-infarction ventricular 
tachycardia. J Am Coll Cardiol 2015;65:1954-1959. 
19. Dinov B, Arya A, Schratter A, Schirripa V, Fiedler L, Sommer P, Bollmann A, 
Rolf S, Piorkowski C, Hindricks G. Catheter Ablation of Ventricular Tachycardia 
and Mortality in Patients With Nonischemic Dilated Cardiomyopathy: Can 
Noninducibility After Ablation Be a Predictor for Reduced Mortality? Circ 
Arrhythm Electrophysiol 2015;8:598-605. 
20. Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular 
tachycardia after catheter ablation is associated with improved survival in patients 
with structural heart disease: An International VT Ablation Center Collaborative 
Group study. Heart Rhythm 2015;12:1997-2007. 
 
 20 
21. Frankel DS, Mountantonakis SE, Robinson MR, Zado ES, Callans DJ, 
Marchlinski FE. Ventricular tachycardia ablation remains treatment of last resort 
in structural heart disease: argument for earlier intervention. J Cardiovasc 
Electrophysiol 2011;22:1123-1128. 
22. Dinov B, Arya A, Bertagnolli L, Schirripa V, Schoene K, Sommer P, Bollmann 
A, Rolf S, Hindricks G. Early referral for ablation of scar-related ventricular 
tachycardia is associated with improved acute and long-term outcomes: results 
from the Heart Center of Leipzig ventricular tachycardia registry. Circ Arrhythm 
Electrophysiol 2014;7:1144-1151. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 21 
Tables 
Table 1: Baseline data 
 No SHD  
(n=98 
patients) 
NICM  
(n=239 
patients) 
ICM  
(n=358 
patients) 
P 
value 
no 
SHD 
vs. 
others 
P 
value 
ICM 
vs. 
NICM 
Age, mean ± SD, years 47±15 52±14 67±10 <0.001 <0.001 
Male gender, % 49 79 86 <0.001 0.02 
LVEF, mean ± SD, % 61±6 40±17 28±12 <0.001 <0.001 
LVEF ≤ 30% 0 68 40 <0.001 <0.001 
Number of failed anti-
arrhythmic drugs, mean ± SD 
1.6±1.3 2.1±1.3 2.6±1.4 <0.001 <0.001 
Failed amiodarone prior to 
ablation, % 
17 65 81 <0.001 <0.001 
Implanted defibrillator, % 0 77 90 <0.001 <0.001 
Cardiac re-synchronization 
device, % 
0 12 20 <0.001 0.01 
NYHA class ≥ II 0 58 56 <0.001 0.8 
Subtype of NICM heart disease, 
n, % of all NICM patients 
Idiopathic dilated 
Arrhythmogenic right 
ventricular dysplasia 
Sarcoidosis 
Valvular 
Congenital 
Other
a
 
  
 
132 (55) 
39 (16) 
12 (5) 
30 (13) 
19 (8) 
7 (3.4) 
   
a
Hypertrophic cardiomyopathy 6, restrictive cardiomyopathy 1 
Abbreviations: ICM-ischemic cardiomyopathy, LVEF-left ventricular ejection fraction; NICM-non-
ischemic cardiomyopathy, NYHA- New York Heart Association Class; Q25-Q75- interquartile range 25%-
75%, SD-standard deviation, SHD-structural heart disease  
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Table 2: Procedural characteristics 
 No SHD  
(n=98 
patients) 
NICM  
(n=239 
patients) 
ICM  
(n=358 
patients) 
P value no 
SHD vs. 
NICM/vs. 
ICM 
P 
value 
ICM 
vs. 
NICM 
Sustained VT as 
indication for procedure 
98 (100) 239 (100) 358 (100) - - 
Total number of VT 
ablation procedures 
performed, (mean ± SD 
of procedures 
performed/patient) 
109 (1.1± 0.4) 341 (1.4± 0.7) 470 (1.3± 0.6) <0.001/0.9 <0.001 
Number of patients 
undergoing: 
1 procedure 
2 procedures 
≥ 3 procedures 
 
88 
9 
1 
 
161 
55 
23 
 
267 
76 
15 
 
- 
 
- 
Interval between first 
and last procedure, 
years, mean ± SD 
(median; IQR 25-75%) 
1.5 ± 2.4 (0.5; 
0.01-2.2) 
1.2 ± 1.8 (0.4; 
0.02-1.8) 
0.6 ± 1.2 (0.07; 
0.01-0.7) 
0.8/0.1 0.003 
Procedural indication of 
VT storm, n/total 
number of procedures 
(%) 
13/109 (12) 84/340 (25) 145/470 (31) 0.007/<0.001 0.06 
Number of inducible 
VTs per procedure, 
mean ± SD 
1.1±0.5 2.4±1.6 2.8±1.7 <0.001 (both) <0.001 
RF ablation time, mean 
± SD, minutes 
11.8±9.6 24.7±21.5 33.3±22.4 <0.001 (both) <0.001 
Fluoroscopy time, mean 
± SD, minutes 
31.3±20 43±21.6 45.1±30.2 <0.001 (both) 0.8 
Origin of idiopathic VT, 
n/number of patients 
(%) 
RV outflow 
tract 
LV outflow 
tract 
LV summit 
Papillary 
muscle 
Aortic-mitral 
continuity or 
mitral annular 
origin 
Right 
parahisian 
Epicardial
a
 
LV lateral 
RV free wall 
Other focal LV 
 
 
53 (54) 
6 (6) 
4 (4) 
1 (1) 
 
3 (3) 
3 (3) 
3 (3) 
4 (4) 
1 (1) 
20 (20) 
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VT (including 
fascicular or 
Purkinje-
related) 
Epicardial ablation 
required during at least 
one procedure, 
n/number of patients 
(%) 
3/98 (3) 71/239 (30) 30/358 (8) <0.001/0.08 <0.001 
Non-RFA requirement 
(transcoronary ethanol 
or surgical 
cryoablation), n/number 
of procedures (%) 
 
0/109 (0) 
 
21/341 (6.2) 
 
21/470 (4.5) 
 
0.003/0.02 
 
0.4 
Acute procedural 
outcome after final 
procedure, % 
Complete 
success 
Partial success 
Failure 
Not tested or 
non-inducible 
at beginning 
 
 
79 
3 
12 
6 
 
 
56 
19 
13 
12 
 
 
60 
20 
9 
11 
 
 
<0.001/0.001 
 
 
0.4 
Major complications, 
n/number of procedures  
(%) 
4/109 (3.7) 23/341 (6.7) 39/470 (8.3) 0.4/0.1 0.4 
 
a
epicardial lateral wall LV 2, epicardial RVOT 1 
Abbreviations (in addition to above): LV-left ventricle; ms-milliseconds, RV-right ventricle; VT-
ventricular tachycardia. 
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Table 3: Factors associated with VA recurrence and all cause mortality 
 
 
Variable Multivariable 
HR for VA 
recurrence 
(95% CI) 
P value Multivariable HR 
for all cause 
mortality (95% CI)  
P value 
Age -  1.05 (1.04-1.06) <0.001 
Male gender -  - - 
LVEF (each 1% 
increase) 
0.99 (0.98-0.99) 0.01 0.96 (0.95-0.97) <0.001 
Type of SHD 
ICM (vs. no 
SHD)
a
 
NICM (vs. no 
SHD) 
 
1.7 (0.9-2.9) 
2.3 (1.3-3.9) 
 
 
0.09 
0.003 
 
 
15.5 (3.8-63.2) 
13.8 (3.4-56.8) 
 
<0.001 
<0.001 
Number of failed anti-
arrhythmic drugs 
1.1 (1.003-1.22) <0.001 - - 
History of VT storm - - - - 
Acute complete 
success  
0.65 (0.52-0.82) <0.001 0.7 (0.58-0.94) 0.01 
Epicardial ablation 1.5 (1.1-2) 0.01 -  
Need for adjunctive 
non-RFA ablation 
- - 1.6 (1.04-2.4) 0.03 
Major complication - - 1.6 (1.1-2.3) 0.03 
VA Recurrence
b
 Not entered - 1.8 (1.4-2.4) <0.001 
a
HR for VA recurrence comparing ICM vs. NICM was 0.7 (95% CI 0.6-0.9, P=0.02); HR 
for all cause mortality comparing NICM vs. ICM: HR 1.1 (95% CI 0.8-1.5), P=0.5 
b
added as a time-dependent co-variate 
 
Abbreviations (in addition to above): RFA-radiofrequency ablation, VA-ventricular arrhythmia.
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Figure Legends 
Figure 1: Survival free of recurrent ventricular arrhythmia in the no structural 
heart disease (no SHD), ischemic cardiomyopathy (ICM) and non-ischemic 
cardiomyoptahy groups (NICM). 
*No SHD vs. ICM P <0.001; No SHD vs. NICM P<0.001; ICM vs. NICM P=0.03  
Figure 2: Overall survival in the no SHD, ICM and NICM groups. 
*P<0.001 between all 3 groups 
Figure 3: Survival free of cardiac transplant in the no SHD, ICM and NICM 
groups. 
*No SHD vs. ICM P =0.08; ICM vs. NICM P=0.002; no SHD vs. NICM P=0.002. 
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